MA29872B1 - Procede d'amelioration de la fonction cognitive - Google Patents

Procede d'amelioration de la fonction cognitive

Info

Publication number
MA29872B1
MA29872B1 MA30850A MA30850A MA29872B1 MA 29872 B1 MA29872 B1 MA 29872B1 MA 30850 A MA30850 A MA 30850A MA 30850 A MA30850 A MA 30850A MA 29872 B1 MA29872 B1 MA 29872B1
Authority
MA
Morocco
Prior art keywords
subject
cognitive function
improving
homozygous
apoe4
Prior art date
Application number
MA30850A
Other languages
English (en)
French (fr)
Inventor
Allen D Roses
Ann M Saunders
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37876831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29872(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of MA29872B1 publication Critical patent/MA29872B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MA30850A 2005-09-22 2008-04-15 Procede d'amelioration de la fonction cognitive MA29872B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71935305P 2005-09-22 2005-09-22
US72737705P 2005-10-17 2005-10-17

Publications (1)

Publication Number Publication Date
MA29872B1 true MA29872B1 (fr) 2008-10-03

Family

ID=37876831

Family Applications (2)

Application Number Title Priority Date Filing Date
MA30849A MA29871B1 (fr) 2005-09-22 2008-04-15 Composition pharmaceutique concue pour ameliorer la fonction cognitive
MA30850A MA29872B1 (fr) 2005-09-22 2008-04-15 Procede d'amelioration de la fonction cognitive

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA30849A MA29871B1 (fr) 2005-09-22 2008-04-15 Composition pharmaceutique concue pour ameliorer la fonction cognitive

Country Status (16)

Country Link
US (2) US20080262047A1 (OSRAM)
EP (2) EP1940403A2 (OSRAM)
JP (2) JP2009508960A (OSRAM)
KR (2) KR20080056731A (OSRAM)
AR (2) AR056527A1 (OSRAM)
AU (2) AU2006295010A1 (OSRAM)
BR (2) BRPI0616192A2 (OSRAM)
CA (2) CA2623210A1 (OSRAM)
CR (2) CR9848A (OSRAM)
EA (2) EA200800880A1 (OSRAM)
IL (2) IL190217A0 (OSRAM)
MA (2) MA29871B1 (OSRAM)
NO (2) NO20081847L (OSRAM)
PE (2) PE20070976A1 (OSRAM)
TW (2) TW200803896A (OSRAM)
WO (2) WO2007038112A2 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
IL187159A0 (en) * 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
WO2009043593A1 (en) * 2007-10-05 2009-04-09 Merz Pharma Gmbh & Co. Kgaa Combination therapy using memantine and glitazones
EP2085120A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
NZ591107A (en) 2008-08-12 2012-08-31 Zinfandel Pharmaceuticals Inc Method of identifying disease risk factors
US20100152249A1 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of The Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
CA2766107A1 (en) * 2009-06-25 2010-12-29 Alcobra Ltd. A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
WO2012053016A1 (en) * 2010-10-22 2012-04-26 Cadila Healthcare Limited Sustained release pharmaceutical compositions of donepezil
AU2011354696B2 (en) * 2011-01-10 2015-03-05 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
US9102666B2 (en) 2011-01-10 2015-08-11 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating Alzheimer's disease
UY34403A (es) 2011-10-21 2013-05-31 Takeda Pharmaceutical Preparación de liberación sostenida
CA2853100A1 (en) * 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
WO2014171542A1 (ja) * 2013-04-19 2014-10-23 武田薬品工業株式会社 放出制御製剤
CA3032036A1 (en) * 2016-07-26 2018-02-01 Ausio Pharmaceuticals, Llc Methods of diagnosing and treating alzheimer's disease with s-equol
US20180153859A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625212B1 (en) * 1992-10-13 2004-03-24 Duke University Methods of detecting alzheimer's disease
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
WO2000035437A2 (en) * 1998-12-17 2000-06-22 Mindset Biopharmaceuticals (Usa), Inc. Improving mental performance by increasing brain insulin sensitivity
JP2007519738A (ja) * 2004-01-30 2007-07-19 アクソニクス，インコーポレイテッド 糖尿病の合併症の治療方法

Also Published As

Publication number Publication date
WO2007038112A2 (en) 2007-04-05
WO2007038112A3 (en) 2007-12-06
WO2007038115A3 (en) 2007-12-13
EA200800880A1 (ru) 2009-02-27
WO2007038115A2 (en) 2007-04-05
BRPI0616192A2 (pt) 2011-06-14
US20080262047A1 (en) 2008-10-23
AR055649A1 (es) 2007-08-29
US20080226719A1 (en) 2008-09-18
EP1940403A2 (en) 2008-07-09
MA29871B1 (fr) 2008-10-03
BRPI0616100A2 (pt) 2011-06-07
AU2006295007A1 (en) 2007-04-05
AR056527A1 (es) 2007-10-10
CA2623204A1 (en) 2007-04-05
EP1926488A2 (en) 2008-06-04
NO20081843L (no) 2008-06-16
TW200803851A (en) 2008-01-16
EA200800879A1 (ru) 2008-10-30
CR9849A (es) 2008-05-21
AU2006295010A1 (en) 2007-04-05
JP2009508960A (ja) 2009-03-05
PE20070618A1 (es) 2007-07-04
IL190224A0 (en) 2008-11-03
CR9848A (es) 2008-06-18
JP2009508959A (ja) 2009-03-05
PE20070976A1 (es) 2007-12-05
CA2623210A1 (en) 2007-04-05
TW200803896A (en) 2008-01-16
KR20080056731A (ko) 2008-06-23
KR20080058413A (ko) 2008-06-25
IL190217A0 (en) 2008-11-03
NO20081847L (no) 2008-06-18

Similar Documents

Publication Publication Date Title
MA29872B1 (fr) Procede d'amelioration de la fonction cognitive
Etebarian et al. The purpose of this study is to determine the relationship between psychological capital and organizational commitment of employees in a trade organization in Iran. The survey type of research was applied and the research perspective is descriptive-correlational in nature. The population included all employees of the organization in 2011 which amounted to 200. Sampling was done randomly at 5% error level using the...
Higuchi et al. Mutations in MME cause an autosomal‐recessive Charcot–Marie–Tooth disease type 2
Yamin et al. ACE ID genotype affects blood creatine kinase response to eccentric exercise
Coutelier et al. GRID2 mutations span from congenital to mild adult-onset cerebellar ataxia
Nazarov et al. The angiotensin converting enzyme I/D polymorphism in Russian athletes
Ma Lead in mammals
Duclot et al. Epigenetic mechanisms underlying the role of brain-derived neurotrophic factor in depression and response to antidepressants
West et al. Better memory functioning associated with higher total and low-density lipoprotein cholesterol levels in very elderly subjects without the apolipoprotein e4 allele
NO20062003L (no) Fremgangsmate og forbindelser for behandling av immunoinflammatoriske forstyrrelser
Nabika et al. The stroke-prone spontaneously hypertensive rat: still a useful model for post-GWAS genetic studies?
Himori et al. Superoxide dismutase/catalase mimetic EUK-134 prevents diaphragm muscle weakness in monocrotalin-induced pulmonary hypertension
NO20061239L (no) Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser
Pasha et al. Variations in angiotensin-converting enzyme gene insertion/deletion polymorphism in Indian populations of different ethnic origins
Hashimoto et al. Effect of systemic administration of D-serine on the levels of D-and L-serine in several brain areas and periphery of rat
Wojtas et al. Neurochemical and behavioral effects of a new hallucinogenic compound 25B-NBOMe in rats
WO2003103585A3 (en) Methods of treating angiogenesis, tumor growth, and metastasis
Negishi et al. Involvement of complement 3 in the salt-sensitive hypertension by activation of renal renin-angiotensin system in spontaneously hypertensive rats
Di Piero et al. Aminergic tone correlates of migraine and tension‐type headache: A study using the tridimensional personality questionnaire
Dong et al. Environment enrichment rescues the neurodegenerative phenotypes in presenilins‐deficient mice
Sargent Synthesis of acetylcholine by excitatory motoneurons in central nervous system of the leech
WO2001020031A3 (en) Polymorphisms in a klotho gene
Bonelli et al. Molecular phylogenetic analysis of Echinococcus granulosus sensu lato infecting sheep in Italy
Altamura et al. What is the relationship among atherosclerosis markers, apolipoprotein E polymorphism and dementia?
Takeda et al. Intrastriatal grafts of fetal ventral mesencephalon improve allodynia-like withdrawal response to mechanical stimulation in a rat model of Parkinson's disease